These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7066751

  • 1. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
    Otton SV, Inaba T, Mahon WA, Kalow W.
    Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
    Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum M, Säwe J, Sjöqvist F.
    Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative pharmacogenetics of sparteine and debrisoquine.
    Inaba T, Vinks A, Otton SV, Kalow W.
    Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
    Boobis AR, Murray S, Kahn GC, Robertz GM, Davies DS.
    Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW, Moody DE.
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [Abstract] [Full Text] [Related]

  • 16. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M, Bertilsson L, Säwe J, Zekorn C.
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [Abstract] [Full Text] [Related]

  • 17. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF.
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L.
    Eur J Clin Pharmacol; 1986 Oct; 30(6):679-84. PubMed ID: 3533565
    [Abstract] [Full Text] [Related]

  • 20. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M.
    Prog Clin Biol Res; 1986 Oct; 214():157-67. PubMed ID: 3523506
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.